AstraZeneca plc (LSE:AZN;
NYSE:AZN) partnered with CytImmune Sciences Inc. (Rockville, Md.) to
evaluate the feasibility of combining an undisclosed preclinical
cancer compound from the pharma with CytImmune's CYT-6091. CytImmune
said the companies plan to conduct preclinical testing throughout
2013 before deciding whether to move a combined compound into the
clinic. CYT-6091, a tumor necrosis factor (TNF)-bearing pegylated
colloidal gold nanoparticle, has completed a Phase I trial in
advanced solid tumors. The partners declined to provide details.
Here we have a perfect
(from investors point of view) magic bullet against cancer: it is a
combination of 3 different parts:
A tumor necrosis
factor – this is the most important part of the drug
Gold nanoparticle –
very sexy and necessary idea to use nanotechnology – no one
investor has to miss it.
And this combination
is PEGylated to hide this shit from immune system
Well, very exciting
comination – for those who believes in nanotechnology, biologicals
and magic bullet combinations!
No comments:
Post a Comment